Intangible Asset Valuation Methodologies Pre-IPO: Choices and Regulatory Expectations

The SFC and HKEX have intensified their scrutiny of intangible asset valuations in IPO prospectuses, a shift driven by the increasing proportion of pre-revenue biotech and technology companies seeking listings under Chapter 18A and Chapter 18C of the Main Board Listing Rules. In 2024, the HKEX rejected two listing applications citing insufficient justification for the valuation of internally generated intangible assets, according to public records of listing decisions. This marks a departure from the prior approach where sponsor-led fair value assessments were often accepted at face value. For CFOs and sponsor teams, the window for relying on generic valuation methodologies has closed; the regulator now demands a granular, auditable linkage between the valuation model, the company’s specific revenue projections, and the contractual rights underpinning the asset.

The Regulatory Framework: From HKEX Guidance to SFC Enforcement

The HKEX’s Listing Decision LD115-2023 set a clear precedent: intangible assets, particularly those arising from research and development or acquired in business combinations, must be valued using methodologies that align with the company’s actual operational stage and revenue trajectory. The decision explicitly cited the requirement under Listing Rule 11.06 that a listing document must contain sufficient information to enable a reasonable investor to make an informed assessment of the issuer’s financial condition. This standard effectively requires that the valuation of intangible assets—such as patents, licenses, and customer relationships—be supported by a discounted cash flow (DCF) model that uses inputs consistent with the company’s historical financial data and industry benchmarks.

The Role of the SFC’s Code of Conduct

The SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC, specifically paragraph 17.6, mandates that sponsors must exercise due diligence in verifying the reasonableness of financial information in a listing document. This extends to intangible asset valuations, where the sponsor must assess whether the methodology adopted by the valuer is appropriate and whether the underlying assumptions—such as revenue growth rates, royalty rates, and discount rates—are consistent with market data. In a 2024 enforcement action against a sponsor, the SFC imposed a fine of HKD 15 million for failing to identify that a DCF model used to value a patent portfolio relied on revenue projections that exceeded the company’s own internal forecasts by 40%.

Interaction with HKMA Prudential Requirements

For financial institutions seeking a listing, the HKMA’s Supervisory Policy Manual (SPM) module CA-G-5 on “Valuation of Intangible Assets” imposes additional constraints. The HKMA requires that intangible assets be measured at fair value less costs to sell, with any impairment recognised immediately in the profit and loss account. This creates a tension for banks listing on the Main Board: the prospectus must present a valuation that satisfies both the HKEX’s disclosure requirements and the HKMA’s prudential standards, often requiring a dual-track analysis that reconciles fair value under HKFRS 13 with regulatory capital treatment.

Methodological Choices: DCF, Market Approach, and Relief-from-Royalty

The selection of a valuation methodology is not a matter of preference but of regulatory defensibility. The HKEX’s Listing Decision LD95-2022 explicitly rejected a market approach for a pre-revenue biotech company, stating that the absence of comparable transactions in the same therapeutic area rendered the method unreliable. The decision mandated the use of a DCF model with a risk-adjusted discount rate derived from the company’s weighted average cost of capital (WACC), which was calculated using a risk-free rate of 3.5% (based on the 10-year HKD government bond yield as of the valuation date) and an equity risk premium of 8.2%.

DCF Modelling: Inputs Under the Microscope

The DCF approach requires four critical inputs: revenue projections, terminal value assumptions, discount rates, and royalty rates (if using the relief-from-royalty method). The SFC has focused on the linkage between these inputs and the company’s contractual rights. For example, if a technology company holds a patent with a remaining legal life of 10 years, the DCF model must cap the projection period at that duration, unless the company can demonstrate that the underlying know-how will generate cash flows beyond the patent’s expiry through trade secret protection. The HKEX’s guidance on Chapter 18A listings requires that revenue projections be supported by phase-by-phase clinical trial data, with a specific reference to the probability of success for each phase—typically 10% for Phase I, 30% for Phase II, and 60% for Phase III, per the Biotechnology Innovation Organization’s 2023 industry report.

Market Approach: Applicability and Limitations

The market approach is viable only when there is a sufficiently large set of comparable arm’s-length transactions involving similar intangible assets. In Hong Kong, this is rare for pre-IPO companies due to the bespoke nature of their assets. The HKEX’s Listing Decision LD102-2024 involved a company that attempted to use a market approach for a customer relationship intangible acquired in a business combination. The regulator rejected this, noting that the comparable transactions cited involved different industries and geographies, and that the company failed to adjust for differences in customer retention rates. The decision required the company to adopt a multi-period excess earnings method (MPEEM), which isolates the cash flows attributable to the intangible asset by deducting returns on other contributory assets.

Relief-from-Royalty Method: A Preferred Path for Patent-Intensive Companies

For companies with a strong patent portfolio, the relief-from-royalty method is increasingly accepted by the HKEX, provided the royalty rate is benchmarked against industry-specific licensing agreements. The SFC’s 2023 thematic review of biotech IPO valuations found that 70% of successful Chapter 18A applicants used this method, with royalty rates ranging from 2% to 8% of net sales, depending on the therapeutic area. The review emphasised that the royalty rate must be derived from comparable licenses, not from a hypothetical negotiation model, and that the rate must be adjusted for the patent’s remaining life and the competitive landscape. A rate of 5% for a monoclonal antibody patent with 12 years of remaining life was deemed reasonable in a 2024 listing decision, while a rate of 3% for a similar asset with 8 years remaining was rejected as insufficiently supported.

Interaction with Business Combinations and Goodwill

When a pre-IPO company has engaged in an acquisition within the three years preceding the listing application, the HKEX requires that the purchase price allocation (PPA) be disclosed in the prospectus, with a detailed breakdown of the fair value assigned to each identifiable intangible asset. The HKEX’s guidance on pro forma financial information (Listing Rule 4.29) mandates that the PPA must be completed before the listing application is submitted, and that the valuation must be performed by an independent valuer with relevant industry experience.

Goodwill Allocation and Impairment Testing

The allocation of goodwill to cash-generating units (CGUs) must reflect the synergies expected from the acquisition. The HKEX’s Listing Decision LD88-2021 rejected a company’s allocation of 60% of goodwill to a CGU that generated only 15% of the combined entity’s revenue, on the grounds that the allocation did not reflect the expected benefits. The decision required the company to reallocate the goodwill based on the relative fair values of the CGUs, using a methodology consistent with HKAS 36. For impairment testing, the HKEX expects that the recoverable amount of each CGU be calculated using a value-in-use model with pre-tax discount rates, and that the assumptions be disclosed in full, including growth rates beyond the five-year projection period, which must not exceed the long-term growth rate of the relevant industry.

The Impact of VIE Structures on Intangible Asset Valuation

For PRC-based companies using a variable interest entity (VIE) structure, the valuation of intangible assets held by the VIE or its subsidiaries introduces additional complexity. The HKEX’s guidance note GL94-18 requires that the VIE agreements—such as exclusive technology licensing agreements—be valued as separate intangible assets, with the cash flows attributable to those agreements isolated from the operating cash flows of the onshore entity. This often requires a two-step valuation: first, the fair value of the VIE’s underlying business, and second, the allocation of that value to the contractual rights under the VIE structure. The SFC has flagged that the discount rate applied to VIE-related cash flows should include a premium for the legal and regulatory risk of the structure, typically 100 to 200 bps above the company’s WACC.

Practical Considerations for Pre-IPO Preparation

For companies preparing for a Main Board listing, the valuation of intangible assets should be addressed at least 12 months before the A1 filing. The independent valuer should be engaged early to conduct a pre-listing valuation that identifies potential gaps in data, such as the absence of a documented royalty rate benchmark or a lack of historical revenue data to support a DCF model. The sponsor must then review the valuation report against the company’s business plan and financial projections, flagging any inconsistencies to the valuer.

Documentation and Audit Trails

The HKEX expects that all assumptions used in the valuation be supported by contemporaneous documentation. For example, if the DCF model assumes a revenue growth rate of 20% for the first three years post-listing, the company must produce a board-approved budget or a market study that justifies that rate. The SFC’s 2024 enforcement action against a sponsor for a failed listing application highlighted that the sponsor failed to obtain the company’s internal forecasts for the period, relying instead on the valuer’s own estimates. The sponsor was fined HKD 8 million and the company’s listing application was withdrawn.

Interaction with the Listing Committee’s Review Process

The Listing Committee may request a live presentation of the valuation methodology during the hearing, particularly for companies with significant intangible assets relative to total assets. In a 2024 hearing for a biotech company, the Committee asked the valuer to explain the choice of discount rate and to provide a sensitivity analysis showing the impact of a 100 bps change in the discount rate on the asset’s fair value. The company was required to file a supplementary valuation report addressing these points, delaying the listing by two weeks. To avoid such delays, the sponsor should prepare a valuation summary that includes a sensitivity analysis for key assumptions, with the results presented in a table format showing the fair value at the base case, a 10% downside, and a 10% upside scenario.

Actionable Takeaways for CFOs and Sponsor Teams

1. Engage an independent valuer with relevant industry experience at least 12 months before the A1 filing, and ensure the valuer’s methodology is documented in a draft report that can be shared with the sponsor and the reporting accountant for review.

2. Prepare a board-approved business plan that includes revenue projections, cost assumptions, and capital expenditure forecasts for the period covered by the DCF model, and ensure these are consistent with the assumptions used in the intangible asset valuation.

3. For patent-intensive companies, benchmark the royalty rate against at least three comparable licensing agreements in the same therapeutic area or technology sector, and document the adjustments made for differences in patent life, market size, and competitive landscape.

4. Ensure that the purchase price allocation for any acquisition within three years of the listing application is completed before the A1 filing, with the fair value of each identifiable intangible asset supported by a separate valuation report from an independent valuer.

5. Prepare a sensitivity analysis for the valuation’s key assumptions—discount rate, revenue growth rate, and royalty rate—and include this in the sponsor’s due diligence file, as the Listing Committee may request it during the hearing.